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ABSTRACT: In footprinting experiments, an increase in D N A cleavage with addition of ligand to a system

may be due to a ligand-induced structural change. Ligand binding also enhances cleavage by displacing
the cleavage agent from ligand-binding sites, thus increasing its concentration elsewhere. The theory and
characteristics of this mass-action enhancement are given, and it is shown how it may be recognized. Results
of DNase I footprinting of small oligomers, with actinomycin D as ligand, are analyzed to reveal which
enhancements are due to mass action, and which can reasonably be ascribed to structural changes. Patterns
in the footprinting plots from our experiments on actinomycin D binding to a 139-base-pair DNA fragment
(with DNase I as a probe) are studied in the same way. The likely origins of these patterns are discussed,
as are enhancements occurring with other probes commonly used in footprinting experiments.

%e binding of drugs and other ligands may induce structural
changes in DNA, which may be detected by a number of
techniques. Since the rate of cleavage at a particular bond
by agents such as DNase I depends on the local DNA structure
(Lomonosoff et al., 1981; Drew, 1984; Suck et al., 1988), a
natural way to study such changes is the footprinting technique. In a footprinting experiment, one measures the amounts
of DNA fragments of different lengths produced by a cleavage
agent, and hence the amount of cutting taking place at various
positions on a DNA oligomer, as a function of the ligand
concentration (Dabrowiak & Goodisman, 1989; Dabrowiak
et al., 1991). The amount of cutting at positions at or near
ligand binding sites on DNA will decrease with ligand concentration because the bound ligand prevents the approach of
the cleavage agent (inhibition), but, at other positions, one
might expect to see changes in cutting rate due to structural
changes in the DNA. It should be noted that ligand-induced
structural changes may lead to increases or decreases in the
observed cutting rate. Thus, Low et al. (1984) observed large
enhancements in cutting by DNase I and DNase I1 at many
sites on a 160-base-pair DNA fragment when echinomycin
was allowed to bind, in addition to inhibition of cutting near
the drug binding sites (having the sequence CpG). These
authors noted two possible explanations for the enhancements:
structural changes in DNA and an attractive interaction between the cleaving protein and the antibiotic, leading to increased concentration of the former near antibiotic-binding
sites. They were able to dismiss the latter explanation.
However, it is now clear (Ward et al., 1988; Dabrowiak &
Goodisman, 1989; Dabrowiak et al., 1991; Portugal, 1989) that
there is a third explanation for rate enhancements in DNase
I footprinting experiments. Increased cutting at sites where
no ligand binds can arise from a mass-action effect, caused
by the bound ligand displacing the cleavage agent away from
some regions of DNA, and thus increasing the concentration
t We ackowledge the American Cancer Society, Grant NP-681, for
supporting this research.

of cleavage agent elsewhere. This means that one may not
automatically interpret cleavage rate enhancements as ligand-induced structural changes, since the mass-action effect,
due to the equilibrium between DNase I and DNA, is always
present. Since mass-action and structural effects may exist
simultaneously (Portugal, 1989; Ward et al., 1988), one must
always consider whether observed enhancements can be explained by mass action alone or if they are the result of a
structural change as well.
Below, we give a model for the mass-action enhancement
and discuss how one can judge whether enhancements observed
in a footprinting experiment have a structural origin. Then,
we consider observed enhancements on small DNA oligomers
and longer fragments, previously noted by other workers, which
may be due to structural changes or mass-action effects. The
experimentally observed intensity enhancements for actinomycin D interacting with a 139-mer that we believe to be
structural in origin are then presented and discussed.
EXPERIMENTAL
PROCEDURES
The quantitative footprinting studies involving actinomycin
D, the 139-base-pairHindIIIINciI restriction fragment of pBR
322 DNA, and DNase I were as earlier described (Ward et
al., 1988). The sequence of the restriction fragment and the
location of strong and weak actinomycin D binding sites are
shown in Figure 1. Autoradiographic spot intensities, corresponding to relative amounts of 54 cleavage products of
different lengths, were measured for 26 actinomycin D concentrations ranging from 0 to 38.8 pM.
The model used to interpret the resulting footprinting plots,
plots of spot intensity as a function of total drug concentration,
is described in detail elsewhere (Goodisman et al., 1992). The
analysis takes into account binding of drug at the various
binding sites, the mass-action enhancement, and binding of
the drug to unlabeled carrier DNA (calf thymus). Correct
description of the carrier, described as a concentration of strong
binding sites and a concentration of weak binding sites, is
important, since it is mainly the equilibria between drug and
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FIGURE 1: Sequence of the 139-base-pairrestriction fragment used
for DNase I footprintingexperiments, with actinomycin D as ligand.
Filled rectangles show the location of strong actinomycin D binding
sites while the unfilled reactangles indicate weak sites.

..
...

54

----(:+*+0

d

0.0
0

-*-&--e--

l

.

. .

-$---&----~

.

m

h

0

a

I I I I I

I T ?

b 2.2 3.b 3.b -5.14

[Actinomycin], pM

6:0T6

7.2 3
J

6.4
m

3: (a) Footprinting plots for 54, 56, 58, and 143 on the
139-mer. Sites 54,56, and 58 exhibit a sudden increase in intensity
at -20 pM while site 143 exhibits a sudden decrease. (b) Footprinting
plots for sites 59,92,96, and 145 on the 139-mer. Sites 59,92, and
96 show sudden increases in intensity at -20 pM while site 145 shows
a decrease. Theoretically calculated footprinting plots are shown as
a broken line.
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FIGURE 2: Footprinting plots for several sites on the 139-mer for low
drug concentrations. Experimental intensities are shown as solid
symbols; intensities calculated from a model including drug-binding
and mass-action effects are shown as open symbols and broken lines.
The pattern of interest is located at 1.8 pM.
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carrier sites that determine the freedrug concentration present
in the system. Parameters in the model, such as binding
constants, were determined to minimize D,the mean-square
deviation between experimental and calculated spot intensities.
Although the value of D was of the same size as that of the
apparent experimental error in the intensities, some systematic
deviations between experimental and calculated footprinting
plots were noted which may indicate structural changes.
Figure 2 shows part of the footprinting plots (intensities for
15 drug concentrations below 6.6 pM) for six cutting sites.
Measured intensities are plotted as solid symbols; intensities
calculated from the model with the best values of the parameters are plotted as open symbols. In Figure 3, the full
footprinting plots for eight other cutting sites are displayed
with calculated intensities plotted as broken curves. We will
be concerned later with two patterns: one at low drug con-

centrations and one near the 20 pM drug concentration.
The first is a slight (about 10%) decrease, followed by an
increase, in intensity, with a minimum for a total drug concentration of about 2 pM. It is seen most clearly on the
footprinting plots for sites 52-56, 80-83, 89, and 90, which
do not show drug binding, but the pattern seems also to be
present, superposed on the intensity decrease due to drug
binding, on the plots for these sites: 62-64,68,69,75-81, 83,
87,92,114,120. The site number refers to the sequence shown
in Figure 1. Scatter in the experimental intensity data for
other sites makes it impossible to state whether this pattern
is present there. By classifying all sites as positive, negative,
or uncertain, we may summarize the situation by saying that
sites from 54 to 103, in a well-resolved region of the autoradiogram, are either positive or uncertain and that sites from
103 to 161, in a poorly resolved region, are either negative or
uncertain.
Another noticeable pattern occurs for total drug concentration between 16 and 24 pM. In this concentration range,
the shapes of a number of footprinting plots change abruptly,
with intensities showing a sharp increase or a sharp decrease
with drug concentration. This results in a drop in the total
cut of almost 25% at total drug concentration of about 20 pM.
In general, binding-type plots show a decrease in intensity in
this range and enhancement-type plots show an increase. Since
footprinting plots for bonds blocked by drug binding to strong
drug sites have very low intensities for a total drug concen-
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tration of 16 pM, it is impossible to state whether they show
this change in intensity, as is true for other low-intensity
footprinting plots. Also, scatter in the experimental intensities
may obscure the intensity changes we are looking for in some
cases and give the impression of abrupt change when none is
actually present in others. With these cautions, we find abrupt
intensity increases in the following enhancement plots: 54,
55, 56, 57, 58, 59, 90, 92, 94, 95, 96, 108, 126, 150. Weakbinding plots with abrupt intensity decreases are 71, 75, 76,
77, 78, 79, 80, 83, 89, 99, 114, 120, 124, 143, 145, 154, and
158. Plots for which intensities are high, but show no abrupt
changes, are 85, 87, 98, 106, 112, 128, 147, 158, and 161.
THEORY
Mass-Action Enhancement. The cleavage rate, and hence
the amount of cleavage, at any bond i of a DNA polymer is
proportional to the local concentration of cleavage agent or
probe, cpi,and the probability that bond i is not blocked by
bound ligand, vi. Thus
(rate), = ki'cPivi

(1)

Structural effects change (rate)i by changing the rate constant
ki'. The mass-action effect increases (rate)i by increasing cpi
by a factor which is the same for all bonds i. Presence of
ligand-induced structural changes in DNA could increase or
decrease k; by different amounts for different bonds i.
The amount of cleavage at any bond of a DNA oligomer
is proportional to the local concentration of cleavage agent or
probe, which is determined by equilibria between unbound or
free probe and probe bound on DNA at the bond. If the
binding constant for probe is much less than the binding
constant for a ligand, binding of a ligand will always displace
a bound probe molecule. If the ligand binds only at certain
sites on DNA, and the probe can bind (and cut) at many sites,
the effect of ligand binding is to reduce the number of sites
available for probe binding. The competition between ligand
and probe takes place on the carrier DNA, if it is present, as
well as on the radiolabeled fragment. Since carriers are
generally in much higher concentration than the radiolabeled
fragment, it is the equilibrium with carrier DNA that determines the free-drug and free-probe concentrations present in
the system.
Let c be the total concentration of probe-binding sites, on
the carrier and on the fragment. For simplicity, we consider
that all of these sites have the same equilibrium binding
constant, K , where
K = cp/(c - cp)(Pt - cp)

(2)

with cpthe concentration of bound probe and pt the total probe
concentration. The concentration of probe at any site is
proportional to cp/c. The equilibrium equation (eq 2) is easily
solved to give
cP = I/,[P, + c + K-' - ((p, + c + K-')2 - 4 ~ p t ) ' / ~ ]
If the ligand blocks a fraction (1 -A of the probe sites, the
concentration of available sites is reduced to fc. The equilibrium is as in eq 2 except that fc is substituted for c and the
concentration of bound probe in the presence of ligand is
cpf =

y2[Pt

+ fc + K-' - (bt+ fc + K-')2 - .If~pt)'/']

E increases as f decreases, as shown below, but it never becomes infinite, even if all the probe sites are blocked. In fact
lim E =
f+
2CPt
(4)
[Pt K-'][Pt c K-' - ((p, + c + K')'- 4 ~ p , ) ' / ~ ]

+

+ +

Usually, not all probe sites can be blocked by ligand because
of the sequence specificity of the latter.
We now show that the slope dE/df is always negative. If
we define a = pt c K-' and p2 = (pt+ c K-1)2- 4cpt,
then
d_E df

+

+ +

This will be negative if
[pt +

+]([

[ + +][
Pt

(3)

(Pt +

>

);

+ c ] - 2cpt

(5)

+
+ +

To show this, note that pt/(pt K-I) < 1, so that
-4c'pt
4c2pt2
O>pt + K-'
(pt K-1)2
and

Therefore

([;

-+c+-

47)'/2

l
J

--

[

111

' Pt+K 7+c-

p t + K-'
which probes eq 5, so dE/df is always negative. Therefore,
the enhancement E increases monotonically from 1 to E(0)
(eq 4), asfgoes from 1 to 0, where 1 -f is the fraction of sites
blocked by the drug.
It is of interest to consider the behavior of E near f = 1,
by examining the first few terms in the power series in 1 -f:
E = 1 cl(l -j) cz(l -A2 .... The first-order coefficient
is

+

+

+

r

c + K-' - pt

.
I

P
Similarly, the second-order coefficient is
c

The enhancement factor is the ratio of local concentrations,
given by

'12

+c+ k l 2 - 4 7 )

+ K-' -pt

I+

c'(-2ptK-')
P3(a-

8)

Higher coefficients all have a similar form, 1 plus terms in
pt and K-'. If K-' is large compared to c and pt, these terms
are negligible and E becomes 1 + (1 -A + (1 -Az +... or
E =fl.
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pM. This is close to what we found (Goodisman et al., 1992)
by minimization of D, which confirms that the mass-action
effect is mainly responsible for the enhancements observed.
If the fraction of sites blocked by drug, 1 - f,is not large
compared to unity, Le., for small ligand concentrations, the
mass-action enhancement isf’ for all cutting sites. Whether
this is in fact true can be ascertained by calculating the “initial
relative slopes” of the footprinting plots for enhancement sites
(Ward et al., 1988). This is done by fitting the intensities for
the lowest ligand concentrations to a linear function of ligand
concentration D,,given by
Zj(Dt) = aj + bjDt
(6)
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FIGURE 4: Enhancement calculated from a model (see eqs 2-5) in
which all probe-binding sites have the same equilibrium constant, K
= 1.5 X lo6 M-’. The total site concentration is c = 2 pM and the
total probe concentration is pt = 0.1 pM. Points show the enhancement
factor E as a function of 1 -f, the fraction of the probe sites blocked
by bound ligand. The dashed straight line is the function E = 1 +
x where x is k(l - A and k is the initial slope of E. The top curve
is E = (1 - x)-’. The middle curve is E = E&?.

Characteristics of Mass-Action Enhancement. The points
in Figure 4 show the enhancement E as a function off, calculated according to eq 3, as well as various approximations
to it (dashed lines). The parameters used for this example were
pt = 1 X lo-’ M, c = 2 X lo4 M, K = 1.5 X lo6 M-l, giving
a maximum enhancement E(0) of 3.5. Calculating k as the
initial slope of our enhancement factor, -dE/dfforf = 1, and
puttingX = k(1 -A, we have plotted 1/(1 -X)vsf, obtaining
the top curve in Figure 4. It is seen to fit the actual enhancement well forfnear 1 but to increase too rapidly forf
smaller than about 0.3; it cannot be correct for smallfsince
it incorrectly becomes infinite when 1 -f = k-’.
Functions which behave like 1/(1- X ) forfnear 1 but drop
below it asfdecreases are the power series, Cy=02with n finite.
The simplest such function is the linear function 1 + X ( n =
l), plotted in Figure 4 as the bottom curve. It is seen that 1
X is a much poorer approximation to the exact E than is
1/(1 - X ) , as is in fact found in the actual calculations on
actinomycin (Goodisman et al., 1992). However, one can get
a good approximation to E by using a higher value of n. The
middle curve in Figure 4, for n = 6, tracks the points well for
the full range off.
In our actinomycin calculation (Goodisman et al., 1992),
we write the enhancement factor as E = (1 - Kecb)-l or as a
finite power series, C;=o(&Cby’, where cb is the concentration
of bound ligand and K, is the enhancement coefficient, whose
value is chosen to minimize D. Note that all footprinting plots,
for inhibition (binding) sites as well as for enhancement sites,
include the effect of enhancement. In inhibitions, E is multiplied by a decreasing function of ligand concentration which
depends on the ligand binding constant, and so gives different
plots for different sites. All the footprinting plots which do
not show the effect of ligand binding, however, are simply
multiples of E. If all can be fit by the same function, within
a multiplying constant, it is suggested that one is observing
a mass-action enhancement.
The value of K, may be estimated a priori. If c is the
concentration of probe-binding sites, and if one bound ligand
blocks n of these, 1 -fshould be wb/c,so K, should be n/c.
For actinomycin, which blocks seven sites from DNA cleavage,
K, = 7 X lo6 M-’ since the concentration of probe sites is 1

+
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where j indexes the cleavage site. The initial relative slope
is bj/aj and should be negative for sites showing inhibition due
to ligand binding and positive for enhancement sites and for
weak ligand-binding sites, if the ligand concentrations used
for the initial relative slopes are not sufficiently high to give
appreciable binding at such sites. Note that, to get the
magnitude of K, from slopes, one requires a plot of Zj vs
bound-drug concentration cb, and calculation of cb requires
a knowledge of drug-binding constants. However, for small
total drug concentration D,, the free-drug and bound-drug
concentrations are linear in Dt.
For enhancement sites, the initial relative slope should be
Kecb/D,,since cb is linear in Dt. This means it should be the
same for all sites. Initial relative slopes have been calculated
for this experiment, with the standard deviations obtained from
the scatter in the footprinting intensities (Ward et al., 1988).
The slopes were statistically the same, except for sites immediately adjacent to drug-binding sites, for which they were
much larger. This was ascribed to an attractive drug-probe
interaction or a distortion of DNA.
Other authors (Low et al., 1984, 1986) have plotted the
quantity Fj = In [Zj(Dt)/Zj(0)]vs site number j , using the
results of only two footprinting experiments, one in the
presence of drug at concentration D, and one in the absence
of drug. In these experiments, D, was large enough so that
binding sites were essentially saturated with drug. Fj > 0 is
an enhancement and Fj < 0 shows the effect of drug binding,
allowing enhancement sites to be identified from a plot of Fj
vs j . A problem with this approach is that no estimate of the
uncertainty of Fj is obtained, as one gets from relative initial
slope plots, so it is not clear whether F/ is really different for
different sites. Furthermore, without footprinting plots (Ij vs
D, for several values of Dt), one cannot know whether all sites
with Fj > 0 are enhancement sites or whether some are also
affected by weak binding. The presence of weak ligand sites
would cause certain Fj to be smaller than others (but still
positive) and the fact that 4 depends on j would then not imply
structural changes. The effect of weak binding is seen in the
139-mer footprinting plots for sites 143 and 145, shown in
Figure 3. Similarly, sites 54-58 all show increased cutting
with added drug, but it is evident from data for drug concentrations above 20 p M that 54 and 55 are affected by a weak
binding site, whereas the others may truly be enhancements.
Of course, values of Fj significantly higher than what can be
explained by mass action do imply that a structural change
is present in addition to the mass-action enhancement.
ANALYSIS
Small Oligomers. For small oligomers with a single ligand-binding site, the analysis of footprinting plots is greatly
simplified (Rehfuss et al., 1990a) because a single ligandbinding equilibrium relates the free-drug and bound-drug
concentrations to Dt:
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Here, D, - c b is the free-drug concentration and c is the total
concentration of ligand-binding sites, which is also the concentration of oligomers. Furthermore, K, can be calculated
directly. Suppose that there are s cutting sites on the oligomer
and that a single bound ligand blocks m of these. Then 1 f = mcb/sc and the enhancement factor is E = (1 - mcb/sc)-l
= (1 - Kecb)-I,or K , = m/sc. Since the maximum concentration of bound ligand possible is c, the maximum enhancement is then somewhere between 1 K,c = 1 + m / s and (1
- K,C)-’ = (1 - m/s)-’. It is likely closer to the latter, since
E = (1 - Kecb)-ltends to overestimate the enhancement slightly
and E = 1 Kecb tends to underestimate it (Figure 4).
For example, for DNase I footprinting experiments, actinomycin D is known to block seven sites from cleavage ( m =
7), four from the size of actinomycin D on DNA, and three
sites due to an amino acid “loop” on the enzyme (Suck et al.,
1988). For a DNA n-mer, there are n - 3 bonds at which
cleavage can take place, since DNase I cannot cut at the last
three or four bonds at the 3‘-ends of the duplex (Lomonosoff
et al., 1981; Suck et al., 1988), so s = n - 3. Then, for a
dodecamer (n = 12), the maximum enhancement is (1 - ’/J1
= 4.5. For a 16-mer, one gets a maximum enhancement of
(1 - 7/13)-1 = 2.2, and for a 20-mer (1 - 7 / 1 , ) - 1 = 1.70.
Lane et al. (1987) performed footprinting experiments for
the duplexes d[(AT),AGCT(AT),], with n = 2, 3, and 4,
corresponding to the three cases of the preceding paragraph.
The drug was actinomycin D, and the cleavage agent was
DNase I. On the 12-mer, inhibited cleavage due to drug
binding occurred at all observed sites but one, for which enhanced cleavage was in evidence. NMR measurements showed
that the drug binds near the GC and not at the ends of the
duplex, where the enhancements occurred. For the 20-mer
(n = 4), cleavage enhancements, smaller in size than those for
the 12-mer, were reported at unblocked sites. Enhancements
for the 16-mer were intermediate between those for the other
duplexes. It was also noted that the ratio of the APT cleavage
rate to the TpA cleavage rate increased with n. The carrier
DNA, which determines the probe concentration, was the same
in all the experiments. Therefore, the cleavage rate enhancements in this case and in others (Huang et al., 1988)
cannot be explained by the mass-action model. Note that when
the probe concentration is large, the mass-action enhancement
is small (if P,>> K-’ and Pt > c, eq 4 shows that E is always
about 1). Thus, it is likely that the rate increases observed
by Lane et al. (1987) are structural in origin.
Multisite DNA. Portugal (1989) studied enhancement of
DNase I cleavage by netropsin binding to the Tyr-T DNA
fragment, attempting to separate out the effects of the three
mechanisms: mass-action, structural changes, and ligandprobe interactions. Netropsin is a minor groove ligand which
does not greatly distort DNA upon binding (Kopka et al.,
1985). It was reported that 70-71% of the variance of the
measured cleavage enhancements could be explained by any
of the three mechanisms. Combinations of any two, or of all
three, likewise explained 70-71% of the variance. This suggests that a large fraction of the variance simply arises from
fluctuations or experimental errors in the measured enhancements. However, since only values of F, (logarithm of
the ratio of cleavage at bond j in the presence of drug to
cleavage in the absence of drug) are given, one has no measure
of experimental error in these experiments.
The reported values of F, are plotted against bond number.
The average of the 28 F, values which are positive is 0.75,

+

+

corresponding to a maximum enhancement of 2.1. Since there
are 47 bonds in this fragment and three netropsin sites, each
of which blocks about 8 bonds from cleavage, and assuming
that the three end bonds cannot be cleaved by DNase I, the
maximum enhancement according to the mass-actibn model
is (1 - 24/u)-1 = 2.2. Thus, the average enhancement observed
is consistent with mass action.
Selected footprinting plots (intensity vs total drug concentration) for the actinomycin D-139-mer interaction are shown
in Figures 2 and 3, together with the footprinting plots calculated according to our model. By seeking the values of the
parameters which minimized the sum of the squared deviations
between experimental intensities and those calculated from
the model, we found values for binding constants and the
enhancement constant K,. The value of K,, 7.1 X lo6 M-l,
is consistent with the mass-action model, which predicts, assuming each bound ligand blocks 7 sites and the concentration
of cutting sites is
M, a value of 7.0 X lo6 M-l. It does
not appear that, with the drug concentrations used, one reaches
the maximum enhancement, which would be about (1 10s/139)-1 = 3.7, since there are about 139 bonds and 15 independent binding sites.
A plot of initial relative slope vs site number for true enhancement sites makes it easy to recognize deviations from
constancy, if any. These deviations, which may be positive
or negative, may be ascribed to structural changes. For actinomycin D and netropsin binding to the 139-mer, we suggested on this basis (Ward et al., 1988) that there were
structural changes adjacent to binding sites. For both drugs,
most of the positive slopes were the same size within the
standard deviations, and the average level of enhancement
could be explained by mass action. Unusually large slopes
were observed for netropsin at sites 52, 53,64, and 68; binding
sites are found at 46-50 (5’-AAATA-3‘) and at 56-62 (5’AATTTAA-3’). For actinomycin, unusually large enhancements were noted for sites 58 and 73, and actinomycin-binding
sites of sequence 5’-XGCX-3’ are found at 5‘-63-66-3‘ and
5’-68-71-3’ (Figure 1).
Obviously, the calculated plots for enhancement sites cannot
fit the experimental intensity data in detail, but only on the
average, because of the scatter in the experimental points.
However, when regular patterns appear in the deviations, they
may indicate real effects which our model cannot take into
account, such as structural changes. In the case of actinomycin
D, one such pattern occurs at very low total drug concentrations, and another occurs at a total drug concentration of about
20 pM.
Figure 2 shows experimental intensities for a number of sites
for drug concentrations below 7 pM. The small decrease and
increase at about 2 pM is evident on some of these. If this
effect is actually due to a structural change induced by drug
binding, we may ask which drug-binding events are involved.
For small drug concentration, the equilibrium that determines
the free-drug concentration Do in terms of the total drug
concentration D, is

where K, is the strong-site binding constant on the carrier and
c is the concentration of these sites. Using the values determined by minimization of D, K, = 1.8 X lo7 M-’ and c = 5
pM, a total drug concentration D, of 2 pM corresponds to a
free-drug concentration of 3.6 X lo-* M. For a site j on the
fragment with binding constant K,, the probability p j that a
drug is bound is determined by the equilibrium
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Kj = Pj/[Do(1 - ~ j ) l

(9)

+

sopj = D&/(1
D&). The two strongest binding sites on
the polymer have the sequence 5’-TGCT-3’ and are found at
positions 62-65 and 136-139. The determined binding constants were 3.5 and 6.4 pM-l, respectively (Goodisman et al.,
1992). Then, with Do = 3.6 X lo-* M and KJ = 6.4 X lo6
M-’, PJ = 0.19; with KJ = 3.5 X lo6 M-l, pJ = 0.11. Other
sites are hardly loading drugs at these concentrations. Further,
the intensity pattern is evident on almost all footprinting plots
from 52 to 103, and apparently it is not present near the
strongest binding site. Thus, the structural change in DNA
would have to start some 30 base pairs away from the drug
and extend some 50 base pairs further. These factors suggest
that this pattern should not be ascribed to a structural change.
The other pattern, for 16-24 p M drug, is a sharp intensity
decrease for binding-type plots and a sharp increase for enhancement-type plots. The effect is found all over the fragment. This suggests that an abrupt increase in drug binding
is occurring at certain sites, producing an abrupt increase in
the effective concentration of DNase I, and hence an increase
in cutting, at unblocked sites.
At a drug concentration of 20 pM, many sites have appreciable drug loading. Equation 8 is not adequate to calculate
Do, because the weak sites on the carrier become important
in determining the free-drug concentration. Our calculations
(Goodisman et al., 1992) show that when Dt = 17.2,20.3,23.8
pM, Do = 3.5, 5.4, and 8.0 pM, respectively. According to
eq 9, if KJ= 2 X lo5 M-l, pJ = 0.41 at Do= 3.5 pM. Thus,
all sites with binding constants greater than or equal to 2 X
lo5 M-I have appreciable drug loading. Thirteen such sites
were identified in our study, and there are probably three
others outside the part of the fragment measured in our
footprinting experiments. Since binding sites are distributed
all over the fragment, except in the regions 45-60 and 85-100,
it is not surprising that the abrupt intensity changes occur for
essentially all cutting sites.
This drug-induced structural change, if that is what is occurring, causes a decrease in cutting by enzyme near drugbinding sites and an increase at other positions. This suggests
that it is associated with increased drug binding, which we
referred to previously as positive cooperativity. In our previous
work (Goodisman et al., 1992), we therefore modeled the effect
as an increase in all binding constants with the amount of drug
bound. This mechanism for such cooperative binding could
well be a change in the structure of the DNA fragment, acting
to increase drug binding rather than to increase cleavage.
DISCUSSION
The local structure of DNA affects the cutting efficiency
of DNase I (Drew & Travers, 1984). Intercalating ligands
would appear to be the most likely to produce structural
changes in DNA which can affect cleavage rates by DNase
I or other probes, but groove-binding ligands may also produce
such changes (Portugal, 1989). Suck et al. (1988) suggest that
the strength of binding, and hence the cutting rate, of DNase
I at a site depends mainly on the local minor groove width,
which is large in regions rich in GC and small in regions rich
in AT. Both kinds of regions then have reduced cutting
compared to random sequence DNA. Bending and torsional
stiffness also have an effect on the cutting by DNase I (Hogan
et al., 1989).
Actinomycin D, though it dimerizes in solution, binds as
a monomer, intercalating in DNA at a site that almost always
contains a G (Krugh et al., 1977; Rill et al., 1989). The
formation of the actinomycin-DNA complex is entropy-driven,

and stacking forces are more important than hydrogen bonding
(Chiao & Krugh, 1977). It seems reasonable that the binding
of actinomycin D alters the stfucture of the polymer. Netropsin should disturb polymer structure less on binding (Kopka
et al., 1985), but it leads to cleavage enhancements similar
to actinomycin D in a footprinting experiment (Ward et al.,
1988; Fox & Waring, 1984). Furthermore, the size of most
of the enhancements’is consistent with the mass-action model.
This suggests that, rather than interpreting cleavage enhancements as evidence of structural change; one should first
consider the mass-action model and then interpret what this
model leaves unexplained as due to structural or other changes.
In addition to mass-action and structural changes, an attractive interaction between bound ligand and cleavage agent
is a possible cause of enhanced binding (Low et ai., 1984;
Rehfuss et al., 1990b; Ward et al., 1988). The larger increase
in DNase I cleavage at bonds near actinomycin D binding sites
may be due to this effect. However, similar increases occur
when the porphyrin Mn-T4 is used as a cleavage agent
(Rehfuss et al., 1990b). Large enhancements in cleavage by
this agent on the 139-merwere observed at sites 60 (near the
Act-D binding site at 62-65) and 95 (near the two sites at
100-105). In view of the dramatically different structures of
Mn-T4 and DNase I, a ligand-cleavage agent interaction is
probably not the correct explanation.
We have considered two possible structural changes on the
139-mer by comparing measured footprinting plots for a large
number of sites with plots calculated from a model (Goodisman
et al., 1992) in which values for binding constants and other
parameters are chosen to give the best possible agreement with
experiment. One effect, the large and rapid changes in cutting
intensity for total drug concentrations between 16 and 24 pM
(free-drug concentrations calculated to be 3.5-8.0 pM),is
apparently delocalized over the entire fragment. For these
drug concentrations, about 16 drug-binding sites, distributed
over almost the entire length of the fragment, are appreciably
loaded. Perhaps a major change in polymer structure occurs,
leading tQa large increase in drug binding at the binding sites
and, by way of the mass-action effect, an increase in cutting
at sites not blocked by drug.
The other possible structural change occurs for a total drug
concentration near 2 pM (free-drug concentration calculated
as 0.04 pM). Since the strongest sites are at 62-65 and
136-139, and the intensity pattern seems to be present for all
sites up to about 93 and absent for sites with higher numbers,
it seems unlikely that this is actually a structural change. Its
origin is unknown.
For small okigomers, one normally has only a single ligand-binding site and only a very few footprinting plots showing
enhancements. With so few enhancement sites, one cannot
use the constancy of the enhancements as evidence for the
mass-action effect, although noticeable deviations from constancy do indicate that other effects are operating. However,
it is easy to calculate what the mass-action enhancement should
be, simply by counting the sites. Deviations from predicted
mass-action enhancements,which may be positive or negative
in sign, may be ascribed to structural changes indicated by
drug binding. On longer fragments, negative deviations from
constant mass-action enhancement may be due to the existence
of weak binding sites. In this case, smaller increases in cutting
rate with drug concentration should occur for groups of contiguous bonds, corresponding to the size of the drug’s inhibition
region.
Enhancements and Other Probes. In addition to DNase I,
the aforementioned mass-action effects are applicableto other
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footprinting probes such as Fe-MPE (Dervan, 1986; Dabrowiak et al., 1989a), the porphyrin Mn-T4 (Dabrowiak et
al., 1989b), and various metal complexes incorporating ophenanthroline as a ligand (Kuwabara et al., 1986; Uchida
et al., 1989). Since these probes must bind in order to cleave
DNA, at low probe to DNA ratios their effective concentration
at all non-ligand-binding sites increases when ligand is added
to the system. The observed rate increases would be subject
to the same analysis as for DNase I.
The case for the alkylating agents dimethyl sulfate (DMS)
and diethyl pyrocarbonate (DEPC), often used as probes in
footprinting experiments (Ephrussi et al., 1985; Portugal et
al., 1988; Jeppesen & Nielsen, 1988), is less certain. If these
agents bind to DNA, they too will exhibit mass-action effects
in the footprinting experiment.
CONCLUSIONS
In this report we show how to analyze DNase I footprinting
data for protein- and drug-induced structural changes in DNA.
Since the ligand and DNase I are in equilibrium with DNA,
varying the concentration of ligand affects the amount of
DNase I bound to DNA. This is because ligand binding to
DNA blocks access of the enzyme to certain sites, thereby
causing the effective concentration of the enzyme to increase
at all non-ligand-binding sites. This mass-action effect, resulting in an increase in the cleavage rate, must occur with
all probes which exist in an equilibrium with DNA. The
enhancement of rate is appreciable when the probe concentration is small.
A ligand-induced structural change in DNA can cause a
change, positive or negative, in the cleavage rate constant near
the ligand site. The mass-action effect leads to a positive
change in the amount of cleavage, which should be equally
strong all over the DNA. In order to identify structural
changes, it is first necessary to account for the rate enhancement due to mass action. Then one may note those sites
having cleavage rates above or below the values expected for
redistribution of the probe molecules on DNA.
Registry No. Actinomycin D,50-76-0.
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